Coronary Stent Market 5-Year Forecast

New from Espicom and FDAnews: All Change in the Coronary Stent Market

TMD

Published September 06, 2010

No area of the medical device industry is changing as fast as coronary stents. To profit from trends and technologies, you must move quickly. But in which direction?

Is the future polymer-free, bioabsorbable polymer or bioabsorbable bare metal and drug-eluting stents? How will new applications, demographics and healthcare trends change the market? And which companies have the right products and pricing to prosper?

Here's where to find the answers — in the only single, easy-to-use source now available.
 
New from Espicom and FDAnews
All Change in the
Coronary Stent Market:
Will New Technologies Challenge
Current Market Leaders?
 
This new report arms you with sharp analysis, up-to-date data, and comprehensive intelligence on the technologies, demographics, developments and companies that are expected to shape coronary stents into a $5.3 billion market by 2015.
 
Prepare for new realities — and opportunities.
 
Here's a complete picture of the coronary stents market. You'll learn how 2006 concerns over bare-metal stent restenosis and a link between drug-eluting stents and thrombosis led to breakthrough research, including three promising innovations now poised to transform the market — and the competitive balance of power.
 
Plus, you'll look inside 30 key companies and look ahead to prepare for new opportunities.
Buy now to get the facts you need today to successfully tie your business decisions to the future of coronary stents, including:
  • Technologies: zero in on polymer-free drug-eluting stents, bioabsorbable
    polymer drug-eluting stents, and bioabsorbable bare metal and drug-eluting
    stents — and how prospects for these technologies will drive the market
    for years to come.
  • R&D and marketing issues, including drug delivery issues facing developers
    of polymer-free drug eluting stents; new developments that may improve the
    prospects for the bare metal stent sector; the impact of competition and
    aggressive pricing; which products currently have European CE Marking;
    who's leading the race to bring bioabsorbable polymer drug-eluting stents
    to market; and more.
  • Demographic and health care trends, how the worldwide growth in coronary
    artery disease and greater access to healthcare in emerging countries
    will affect the market for stents.
  • New applications, including opportunities for stents to be used in the treatment
    of diabetes, in-stent restenosis, and small- and multi-vessel disease.
  • Companies: A company-by-company review of major players Boston
    Scientific, Cordis, Medtronic and Abbott; and competitive analysis and
    inside intelligence on 30 companies active in the drug-eluting stent
    sector — who they are, their product portfolios, projected growth,
    patent disputes and more.
  • Future markets: A concise review of potential future markets for stent
    technologies for treating new diseases.
 
Buy Now!
All Change in the Coronary Stent Market: Will New Technologies Challenge Current Market Leaders? is published by Espicom and offered by FDAnews in print or PDF format for $1,215.

Act now: place your order here. (Add $10 shipping and handling per book for printed books shipped to the U.S. and Canada, or $35 per book for books shipped elsewhere. Virginia residents, please add 5 percent sales tax.)
No more results found.
No more results found.